{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:18:28Z","timestamp":1793902708134,"version":"4.8.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.neurot.2026.e00913","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:05:18Z","timestamp":1777935918000},"page":"e00913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Current and emerging therapies in IDH-mutant glioma"],"prefix":"10.1016","volume":"23","author":[{"given":"Vihang","family":"Nakhate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y.","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Supplement_6","key":"10.1016\/j.neurot.2026.e00913_bib1","doi-asserted-by":"crossref","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2017\u20132021","volume":"26","author":"Price","year":"2024","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00913_bib2","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00913_bib3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1470-2045(10)70053-X","article-title":"Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?","volume":"12","author":"Kloosterhof","year":"2011","journal-title":"Lancet Oncol"},{"issue":"5897","key":"10.1016\/j.neurot.2026.e00913_bib4","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00913_bib5","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00913_bib6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","article-title":"The implications of IDH mutations for cancer development and therapy","volume":"18","author":"Pirozzi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00913_bib7","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00401-009-0561-9","article-title":"Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas","volume":"118","author":"Hartmann","year":"2009","journal-title":"Acta Neuropathol"},{"issue":"19","key":"10.1016\/j.neurot.2026.e00913_bib8","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1038\/onc.2011.416","article-title":"Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production","volume":"31","author":"Ward","year":"2012","journal-title":"Oncogene"},{"issue":"16_suppl l","key":"10.1016\/j.neurot.2026.e00913_bib9","article-title":"Incidence of non-canonical IDH mutations and IDH co-mutations in a multicenter prospective study of patients with glioma","volume":"41","author":"Cabezas-Camarero","year":"2023","journal-title":"J Clin Orthod"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00913_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"issue":"7390","key":"10.1016\/j.neurot.2026.e00913_bib11","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00913_bib12","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/s41591-018-0095-6","article-title":"Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate","volume":"24","author":"Bunse","year":"2018","journal-title":"Nat Med"},{"issue":"6705","key":"10.1016\/j.neurot.2026.e00913_bib13","doi-asserted-by":"crossref","first-page":"eadl6173","DOI":"10.1126\/science.adl6173","article-title":"Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity","volume":"385","author":"Wu","year":"2024","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00913_bib14","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/neuonc\/nox183","article-title":"Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications","volume":"20","author":"Malta","year":"2018","journal-title":"Neuro Oncol"},{"issue":"7390","key":"10.1016\/j.neurot.2026.e00913_bib15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nature10866","article-title":"IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype","volume":"483","author":"Turcan","year":"2012","journal-title":"Nature"},{"issue":"26","key":"10.1016\/j.neurot.2026.e00913_bib16","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","article-title":"Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas","volume":"372","author":"Cancer Genome Atlas Research Network","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00913_bib17","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/modpathol.2013.90","article-title":"The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas","volume":"26","author":"Abedalthagafi","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.neurot.2026.e00913_bib18","first-page":"noae107","article-title":"The biological significance of tumor grade, age, enhancement and extent of resection in IDH mutant gliomas: how should they inform treatment decision in the era of IDH inhibitors? Invited review","author":"van den Bent","year":"2024","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00913_bib19","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/cncr.32708","article-title":"Seizures in patients with cancer","volume":"126","author":"Gonzalez Castro","year":"2020","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00913_bib20","first-page":"381","article-title":"Brain and other central nervous system tumor statistics, 2021","volume":"71","author":"Miller","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00913_bib21","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S1470-2045(25)00534-0","article-title":"A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group","volume":"26","author":"Karschnia","year":"2025","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.neurot.2026.e00913_bib22","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma","volume":"374","author":"Buckner","year":"2016","journal-title":"N Engl J Med"},{"issue":"29","key":"10.1016\/j.neurot.2026.e00913_bib23","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1200\/JCO.19.02983","article-title":"Comprehensive genomic analysis in NRG Oncology\/RTOG 9802: a phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma","volume":"38","author":"Bell","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00913_bib24","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","article-title":"Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402","volume":"31","author":"Cairncross","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00913_bib25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","article-title":"Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951","volume":"31","author":"van den Bent","year":"2013","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.neurot.2026.e00913_bib26","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1200\/JCO.21.02543","article-title":"Joint final report of EORTC 26951 and RTOG 9402: phase III trials with procarbazine, lomustine, and vincristine chemotherapy for anaplastic oligodendroglial tumors","volume":"40","author":"Lassman","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00913_bib27","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/neuonc\/nor040","article-title":"International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors","volume":"13","author":"Lassman","year":"2011","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00913_bib28","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/nop\/npac004","article-title":"Short-term outcomes associated with temozolomide or PCV chemotherapy for 1p\/19q-codeleted WHO grade 3 oligodendrogliomas: a national evaluation","volume":"9","author":"Lamba","year":"2022","journal-title":"Neuro-Oncol Pract"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00913_bib29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.24.00049","article-title":"Survival outcomes associated with first-line procarbazine, CCNU, and vincristine or temozolomide in combination with radiotherapy in IDH-mutant 1p\/19q-codeleted grade 3 oligodendroglioma","volume":"43","author":"Kacimi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00913_bib30","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1470-2045(21)00090-5","article-title":"Adjuvant and concurrent temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study","volume":"22","author":"van den Bent","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00913_bib31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(25)00614-X","article-title":"Concurrent and adjuvant temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial","volume":"27","author":"van den Bent","year":"2026","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00913_bib32","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/neuonc\/noaf133","article-title":"Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4","volume":"27","author":"Lasica","year":"2025","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e00913_bib33","first-page":"JCO2501204","article-title":"STELLAR: phase III, randomized, open-label study of eflornithine plus lomustine versus lomustine alone in patients with recurrent grade 3 astrocytoma","volume":"1","author":"Colman","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00913_bib34","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2352-3026(19)30284-4","article-title":"Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial","volume":"7","author":"Stein","year":"2020","journal-title":"Lancet Haematol"},{"issue":"25","key":"10.1016\/j.neurot.2026.e00913_bib35","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00913_bib36","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"issue":"29","key":"10.1016\/j.neurot.2026.e00913_bib37","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1200\/JCO.19.03327","article-title":"Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma","volume":"38","author":"Mellinghoff","year":"2020","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.neurot.2026.e00913_bib38","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-21-0611","article-title":"Vorasidenib, a dual inhibitor of mutant IDH1\/2, in recurrent or progressive glioma; results of a first-in-human phase I trial","volume":"27","author":"Mellinghoff","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00913_bib39","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41591-022-02141-2","article-title":"Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial","volume":"29","author":"Mellinghoff","year":"2023","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00913_bib40","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-Mutant low-grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00913_bib41","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S1470-2045(25)00472-3","article-title":"Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"26","author":"Cloughesy","year":"2025","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00913_bib42","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11910-024-01378-3","article-title":"The role of mutant IDH inhibitors in the treatment of glioma","volume":"24","author":"Nakhate","year":"2024","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00913_bib43","first-page":"vdae227","article-title":"Ivosidenib for the treatment of IDH1-mutant glioma, grades 2\u20134: tolerability, predictors of response, and outcomes","volume":"7","author":"Lanman","year":"2025","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.neurot.2026.e00913_bib44","article-title":"WHO grade loses its prognostic value in molecularly defined diffuse lower-grade gliomas","volume":"11","author":"Carstam","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00913_bib45","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00401-010-0725-7","article-title":"Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective","volume":"120","author":"van den Bent","year":"2010","journal-title":"Acta Neuropathol"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00913_bib46","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1093\/jnen\/nlz082","article-title":"Mitotic Index thresholds do not predict clinical outcome for IDH-mutant astrocytoma","volume":"78","author":"Yoda","year":"2019","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00913_bib48","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/neuonc\/noac155","article-title":"The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas","volume":"25","author":"Natsume","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e00913_bib49","first-page":"noaf258","article-title":"Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-na\u00efve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas","volume":"8","author":"Arakawa","year":"2025","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00913_bib50","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/neuonc\/noac139","article-title":"Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase Ib\/II trial","volume":"25","author":"de la Fuente","year":"2023","journal-title":"Neuro Oncol"},{"issue":"16_suppl","key":"10.1016\/j.neurot.2026.e00913_bib51","first-page":"2013","article-title":"Phase 1 study of HMPL-306, an inhibitor of mutant IDH1\/IDH2 (mIDH1\/2), in Western patients (pts) with advanced mIDH solid tumor, including glioma","volume":"43","author":"Rodon Ahnert","year":"2025","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.neurot.2026.e00913_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114034","article-title":"REVOLUMAB: a phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas","volume":"202","author":"Picca","year":"2024","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00913_bib53","doi-asserted-by":"crossref","first-page":"oyaf362","DOI":"10.1093\/oncolo\/oyaf362","article-title":"Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations","volume":"30","author":"Nguyen","year":"2025","journal-title":"Oncologist"},{"issue":"7514","key":"10.1016\/j.neurot.2026.e00913_bib54","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nature13387","article-title":"A vaccine targeting mutant IDH1 induces antitumour immunity","volume":"512","author":"Schumacher","year":"2014","journal-title":"Nature"},{"issue":"7854","key":"10.1016\/j.neurot.2026.e00913_bib55","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-021-03363-z","article-title":"A vaccine targeting mutant IDH1 in newly diagnosed glioma","volume":"592","author":"Platten","year":"2021","journal-title":"Nature"},{"issue":"375","key":"10.1016\/j.neurot.2026.e00913_bib56","doi-asserted-by":"crossref","first-page":"eaal2463","DOI":"10.1126\/scitranslmed.aal2463","article-title":"2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity","volume":"9","author":"Sulkowski","year":"2017","journal-title":"Sci Transl Med"},{"issue":"7813","key":"10.1016\/j.neurot.2026.e00913_bib57","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41586-020-2363-0","article-title":"Oncometabolites suppress DNA repair by disrupting local chromatin signalling","volume":"582","author":"Sulkowski","year":"2020","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00913_bib58","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/neuonc\/noae072","article-title":"DNA damage response in brain tumors: a society for neuro-oncology consensus review on mechanisms and translational efforts in neuro-oncology","volume":"26","author":"Rahman","year":"2024","journal-title":"Neuro Oncol"},{"issue":"13","key":"10.1016\/j.neurot.2026.e00913_bib59","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.molcel.2023.05.026","article-title":"Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting homologous recombination","volume":"83","author":"Schvartzman","year":"2023","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00913_bib60","first-page":"vdae078","article-title":"Olaparib in recurrent isocitrate dehydrogenase mutant high-grade glioma: a phase 2 multicenter study of the POLA network","volume":"6","author":"Esparragosa Vazquez","year":"2024","journal-title":"Neurooncol Adv"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00913_bib61","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1158\/2767-9764.CRC-22-0436","article-title":"Multicenter phase II trial of the PARP inhibitor olaparib in recurrent IDH1- and IDH2-mutant glioma","volume":"3","author":"Fanucci","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"16_suppl","key":"10.1016\/j.neurot.2026.e00913_bib62","first-page":"2013","article-title":"A phase II trial of olaparib and durvalumab in patients with recurrent IDH-mutated gliomas","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Orthod"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00913_bib63","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-18255-9","article-title":"Assessment of brain penetration and tumor accumulation of niraparib and olaparib: insights from multimodal imaging in preclinical models","volume":"15","author":"Groseclose","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2026.e00913_bib64","first-page":"noaf246","article-title":"Phase I\/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent IDH mutant gliomas","volume":"16","author":"Schiff","year":"2025","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00913_bib65","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ccr.2010.08.009","article-title":"Targeting mitochondrial glutaminase activity inhibits oncogenic transformation","volume":"18","author":"Wang","year":"2010","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00913_bib66","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cell.2018.08.038","article-title":"Transaminase inhibition by 2-Hydroxyglutarate impairs glutamate biosynthesis and redox homeostasis in glioma","volume":"175","author":"McBrayer","year":"2018","journal-title":"Cell"},{"issue":"13_Supplement","key":"10.1016\/j.neurot.2026.e00913_bib67","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1158\/1538-7445.AM2019-3870","article-title":"Abstract 3870: the addition of CB-839 to temozolomide significantly reduces glioma aspartate and glutamate in an IDH mutated patient derived glioma xenograft model","volume":"79","author":"Kizilbash","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.neurot.2026.e00913_bib68","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.canlet.2020.12.038","article-title":"Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models","volume":"502","author":"Wicker","year":"2021","journal-title":"Cancer Lett"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00913_bib69","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ccell.2022.07.011","article-title":"De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma","volume":"40","author":"Shi","year":"2022","journal-title":"Cancer Cell"},{"issue":"479","key":"10.1016\/j.neurot.2026.e00913_bib70","doi-asserted-by":"crossref","first-page":"eaaq1427","DOI":"10.1126\/scitranslmed.aaq1427","article-title":"IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response","volume":"11","author":"N\u00fa\u00f1ez","year":"2019","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00913_bib71","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.15252\/emmm.201707729","article-title":"Altered metabolic landscape in IDH-mutant gliomas affects phospholipid, energy, and oxidative stress pathways","volume":"9","author":"Fack","year":"2017","journal-title":"EMBO Mol Med"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00913_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.112283","article-title":"Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclib","volume":"28","author":"Pang","year":"2025","journal-title":"iScience"},{"issue":"7785","key":"10.1016\/j.neurot.2026.e00913_bib73","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1775-1","article-title":"Longitudinal molecular trajectories of diffuse glioma in adults","volume":"576","author":"Barthel","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00913_bib74","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/ng.3457","article-title":"Integrated genomic characterization of IDH1-mutant glioma malignant progression","volume":"48","author":"Bai","year":"2016","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00913_bib75","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s41588-021-00874-3","article-title":"Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer","volume":"53","author":"Kocakavuk","year":"2021","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00913_bib76","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00401-023-02639-0","article-title":"CDKN2A\/B mutations and allele-specific alterations stratify survival outcomes in IDH-mutant astrocytomas","volume":"146","author":"Hickman","year":"2023","journal-title":"Acta Neuropathol"},{"issue":"14","key":"10.1016\/j.neurot.2026.e00913_bib77","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1158\/1078-0432.CCR-24-0562","article-title":"CDKN2A\/B homozygous deletion sensitizes IDH-mutant glioma to CDK4\/6 inhibition","volume":"30","author":"Nasser","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00913_bib78","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11060-024-04661-y","article-title":"Loss of methylthioadenosine phosphorylase immunoreactivity correlates with poor prognosis and elevated uptake of 11C-methionine in IDH-mutant astrocytoma","volume":"168","author":"Yamamura","year":"2024","journal-title":"J Neuro Oncol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00913_bib79","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","article-title":"MTAP deletions in cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 axis","volume":"15","author":"Marjon","year":"2016","journal-title":"Cell Rep"},{"issue":"16_suppl","key":"10.1016\/j.neurot.2026.e00913_bib80","first-page":"3008","article-title":"A phase 1 study of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients (pts) with recurrent high-grade glioma or uveal melanoma (UM)","volume":"41","author":"Monga","year":"2023","journal-title":"J Clin Orthod"},{"issue":"7584","key":"10.1016\/j.neurot.2026.e00913_bib81","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature16490","article-title":"Insulator dysfunction and oncogene activation in IDH mutant gliomas","volume":"529","author":"Flavahan","year":"2016","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00913_bib82","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.18632\/oncotarget.1408","article-title":"5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft","volume":"4","author":"Borodovsky","year":"2013","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00913_bib83","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.18632\/oncotarget.1412","article-title":"Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor decitabine","volume":"4","author":"Turcan","year":"2013","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00913_bib84","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/neuonc\/noy146","article-title":"Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide","volume":"21","author":"Yamashita","year":"2019","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00913_bib85","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/neuonc\/noaa074","article-title":"5-Azacitidine in patients with IDH1\/2-mutant recurrent glioma","volume":"22","author":"Federici","year":"2020","journal-title":"Neuro Oncol"},{"issue":"Supplement_5","key":"10.1016\/j.neurot.2026.e00913_bib86","doi-asserted-by":"crossref","first-page":"v85","DOI":"10.1093\/neuonc\/noad179.0329","article-title":"CTNI-47. Dose ESCALATION OF ASTX727 IN adult patients with recurrent\/progressive NON-ENHANCING IDH mutant gliomas","volume":"25","author":"Arrillaga-Romany","year":"2023","journal-title":"Neuro Oncol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:57:30Z","timestamp":1792720650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926000838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":85,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1878747926000838"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00913","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and emerging therapies in IDH-mutant glioma","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00913","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00913"}}